Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

10/01/2026, 1:00 PM • GlobeNewswire

Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032

The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.

09/28/2026, 4:58 AM • GlobeNewswire

Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig

ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.

09/24/2026, 5:54 AM • GlobeNewswire

Functional Foods and Beverages Market to Reach $591.7 Billion by 2030, Driven by Rising Consumer Demand for Preventive Health Nutrition

The global functional foods and beverages market is projected to grow from $365.1 billion in 2024 to $591.7 billion by 2030, with a CAGR of 8.6%. Growth is driven by consumer shift toward preventive health nutrition, premiumization, beverage innovation, and expansion in Asia-Pacific. North America leads with 34.3% market share, while emerging technologies like microbiome science and AI-driven personalization reshape competition.

09/23/2026, 5:58 AM • GlobeNewswire

Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.

09/22/2026, 1:00 PM • GlobeNewswire

The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?

The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.

09/22/2026, 12:10 PM • The Motley Fool

Should You Invest $1,000 in SCHD Right Now?

The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on high-quality dividend-paying stocks positions it well for further gains.

09/22/2026, 5:20 AM • The Motley Fool

3 Dividend Stocks to Buy and Hold for 10 Years

The article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.

09/18/2026, 6:13 PM • The Motley Fool

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside

Ken Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.

09/14/2026, 11:15 PM • The Motley Fool

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King

Abbott Laboratories, a Dividend King with 54 consecutive years of dividend increases, is positioned as a defensive investment for potential market downturns. The company reported strong Q2 results with 13% sales growth and raised its full-year EPS guidance. With a 46% payout ratio and growth catalysts from medical devices and its $21 billion Exact Sciences acquisition in cancer diagnostics, Abbott offers both income stability and growth potential.

09/08/2026, 5:15 AM • The Motley Fool

Where Will SCHD Stock Be in 5 Years?

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.

09/06/2026, 12:23 PM • The Motley Fool

Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?

Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.

09/05/2026, 8:15 AM • The Motley Fool

Baby Food & Infant Formula Market Size to Reach USD 74.30 Billion by 2035 | Report by SNS Insider

The global Baby Food and Infant Formula Market was valued at USD 40.37 billion in 2025 and is projected to reach USD 74.30 billion by 2035, growing at a CAGR of 6.29%. Growth is driven by urbanization, increasing parental health consciousness, demand for organic/premium products, and e-commerce expansion. However, recent product recalls by major manufacturers highlight safety concerns in the industry.

09/04/2026, 6:30 PM • GlobeNewswire

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

09/04/2026, 10:54 AM • GlobeNewswire